EBS
Emergent BioSolutions Inc.
Set alert
- YTD
- -44.90%
- 1 year
- -46.96%
- Open
- 7.11
- Prev close
- 7.22
- Mkt cap
- 349.17M
- Vol
- 754.44K
- Avg vol
- 1.23M
- EPS
- -3.40
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.77
- High
- 7.30
- Forward P/E
- 2.73
- Beta
- 1.57
- Short ratio
- 4.54
- Inst. own
- 60.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 9.27
- 200-d avg
- 7.13
- 1y target
- 12.00
Key statistics
- Market cap
- 441.60M
- Enterprise value
- 964.99M
- Trailing P/E
- 0.00
- Forward P/E
- 2.73
- PEG ratio
- 0.00
- Price / sales
- 0.39
- Price / book
- 0.87
- EPS (TTM)
- -3.91
- Beta
- 1.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -18.55%
- Revenue (TTM)
- 1.13B
- Revenue growth
- 8.60%
- Free cash flow
- 89.59M
- Total cash
- 149.90M
- Total debt
- 676.00M
- Return on equity
- -34.64%
- Shares outstanding
- 54.18M
- Short % of float
- 15.53%
- 50-day average
- 9.27
- 200-day average
- 7.13
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.64.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | 0.49 | 1.37 | +0.88 | +179.59% |
| Aug 6, 2024 | Jun 1, 2024 | -0.97 | -2.32 | -1.35 | -139.18% |
| May 1, 2024 | Mar 1, 2024 | 0.00 | 0.59 | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -0.33 | -0.77 | -0.44 | -133.33% |
| Aug 8, 2023 | Jun 1, 2023 | -0.98 | -1.06 | -0.08 | -8.16% |
| May 9, 2023 | Mar 1, 2023 | -1.67 | -3.17 | -1.50 | -89.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Benchmark | main | Buy | Buy |
| Sep 13, 2024 | Rodman & Renshaw | reit | Buy | Buy |
| Aug 22, 2024 | Rodman & Renshaw | init | — | Buy |
| Aug 16, 2024 | Benchmark | reit | Buy | Buy |
| Aug 9, 2024 | Benchmark | reit | Buy | Buy |
| Jul 3, 2024 | Benchmark | reit | Buy | Buy |
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- emergentbiosolutions.com
News
- Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
- Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
- Novavax Shorts on Edge as Russia Plague Fears Spread
- Russian plague outbreak could boost these under-the-radar pharma stocks
- Emergent Biosolutions (NYSE:EBS) Stock: Insider Paul Anthony Williams Sells 3,000 Shares
- Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Consensus Price Target of $10.00
- Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS)
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
Your note
Sign in to keep a note on EBS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAYAL SUJATA TYAGI | Director | Stock Award(Grant) | May 22, 2024 | 63,129 |
| DEGOLYER DONALD W | Director | Sale | Nov 11, 2024 | 111,100 |
| FOWLER NEAL FRANKLIN | Director | Stock Award(Grant) | May 22, 2024 | 136,100 |
| FOX JENNIFER LYNNE | General Counsel | Stock Award(Grant) | Jul 10, 2024 | 186,382 |
| HARTZEL WILLIAM | Officer | Stock Award(Grant) | Jul 10, 2024 | 48,107 |
| KATKIN KEITH A | Director | Stock Award(Grant) | May 22, 2024 | 59,872 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 6.27% | 3,397,626 | 27.69M | Sep 29, 2024 |
| Marshall Wace LLP | 4.60% | 2,494,584 | 20.33M | Sep 29, 2024 |
| Charles Schwab Investment Management, Inc. | 4.11% | 2,224,727 | 18.13M | Sep 29, 2024 |
| Blackrock Inc. | 3.68% | 1,993,680 | 16.25M | Sep 29, 2024 |
| State Street Corporation | 3.53% | 1,911,327 | 15.58M | Sep 29, 2024 |
| American Century Companies Inc | 3.20% | 1,733,045 | 14.12M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Schwab Strategic Tr-Schwab Fundamental U.S. Small Company Index ETF | 4.36% | 2,359,820 | 19.23M | Aug 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.06% | 1,655,564 | 13.49M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.02% | 1,636,319 | 13.34M | Sep 29, 2024 |
| Avantis U.S. Small Cap Value ETF | 2.63% | 1,425,865 | 11.62M | Sep 29, 2024 |
| Invesco ETF Tr-Invesco FTSE RAFI US 1500 Small-Mid ETF | 1.66% | 900,912 | 7.34M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.51% | 815,636 | 6.65M | Sep 29, 2024 |